Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas

G Ghilardi, E A Chong,J Svoboda,P Wohlfarth, S D Nasta, S Williamson, J D Landsburg, J N Gerson,S K Barta,R Pajarillo, J Myers,A I Chen,L Schachter, R Yelton,H J Ballard, A Hodges Dwinal, S Gier, D Victoriano, E Weber, E Napier,A Garfall,D L Porter,U Jäger, R T Maziarz,M Ruella,S J Schuster

Annals of Oncology（2022）

引用 20|浏览19

暂无评分

摘要

•Bendamustine is an effective lymphodepletion regimen before tisagenlecleucel in patients with relapsed/refractory lymphomas.•Bendamustine lymphodepletion has reduced hematological toxicities and infectious complications compared with Flu/Cy.•CRS, neurotoxicity, and hospital utilization are lower in patients treated with bendamustine compared with Flu/Cy.

查看译文

关键词

CAR T cell,lymphodepletion,tisagenlecleucel,bendamustine,lymphoma,toxicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要